Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Christchurch. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
LTG-001 is being developed for the treatment of acute (short-term) and chronic (long-term) pain. One in five New Zealanders live with persistent pain, making it hard to sleep, work and enjoy life. Current pain therapies are limited and may increase risk of abuse of dependence. There is a large unmet need for new, more effective pain therapies to be available to people who need them.
LTG-001 works by inhibiting (blocking) a certain pathway in the cells which control certain pain sensing neurons. LTG-001 is a non-opioid, non-NSAID (non-steroidal anti-inflammatory) and non-narcotic based pain-relief. It is hoped that, by blocking this pathway in the cells, LTG-001 may be an effective treatment for acute or chronic pain while reducing the likelihood for abuse and dependence.
This study (2023 FULL 18297) is being funded by Latigo and has been approved by the Health and Disability Ethics Committee.
Study Candidates
- Be aged 18-55 years
- Are in good health
- Have a BMI (Body Mass Index) between 18 – 32 kg/m2
- Not currently taking any regular prescription medications for your health (e.g., anti-depressants)
- Does not smoke or vape
What is Involved?
Study Visits: 3-night stay
Outpatient visits: 2 visits
Reimbursement: $2, 450 (less tax)